貝瑞基因股票討論區

Berry Genomics Co., Ltd. could likely eliminate its debt due to a conservative balance sheet. However, the company's revenue slip and negative EBIT over the last twelve months make it seem too risky.

Investors' belief that the company will underperform the broader industry may be causing the low P/S ratio. The declining revenues and recent medium-term conditions could continue to disappoint shareholders and form a barrier for the share price.

Berry Genomics' continuous share price and revenue decline signals the risk of investing in unprofitable firms. Last year's performance suggests unresolved challenges. Investors should consider these risks and ensure they invest in high-quality businesses.

Declining revenue at Berry Genomics Co.,Ltd along with anticipated slow growth raises concerns for a low P/S ratio and falling shares. The medium-term trends suggest no significant upward movement in share price soon.

Even with a conservative balance sheet, Berry Genomics Ltd. endures worrying performance with EBIT loss and diminishing revenues in the past year, threatening its shareholders and investors.